Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®
January 11, 2022
Ryan Allway January 11th, 2022 Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health REHOVOT, Israel, Jan. 11, 2022 /PRNewswire/ — Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that the Israeli... Read more
